Updates by Region:
Need Training?
Build a solid foundation in science, formulation and product development—find out more!
Most Popular in:
Europe
New in Europe (page 10 of 11)
May 06, 2006 | 04:54 PM CDT
Colipa Welcomes Sunscreen Product Consultation
Colipa welcomes the European Commission’s plan for a public consultation on the drafted “Recommendation on the Efficacy of Sunscreen Products” and related claims.
Mar 24, 2006 | 03:53 PM CST
EFfCI Publishes GMP Guide for Cosmetic Ingredients
The European Federation for Cosmetic Ingredients (EFfCI) released its Good Manufacturing Practice (GMP) Guide.
Feb 02, 2006 | 02:56 PM CST
EU to Move Forward with Research Funding Program
The leaders of the European Union (EU) reportedly plan to move forward making a decision regarding the region's R&D funding program.
Jan 30, 2006 | 11:27 AM CST
European Commission Approves Fentanyl HCl Iontophoretic Transdermal System
The European Commission has granted marketing authorization in the 25 member states of the European Union for the use of Fentanyl hydrochloride (HCl) Iontophoretic Transdermal System (ITS) 40 mcg/dose...
Jan 04, 2006 | 10:40 AM CST
EUROPEN Publishes Packaging Standards Guide
EUROPEN has published a new edition of its guide to assist personal care manufacturers with packaging standards and regulations.
Dec 23, 2005 | 05:41 PM CST
The 7th International Conference on Cosmetic Regulations
By: David C. Steinberg, Steinberg & Associates
On October 20-22, 2003, more than 300 delegates gathered at the Le Meridien Grand Pacific Hotel on Tokyo Bay for the 7th International Conference on Cosmetic Regulations. Every three years, U.S., EU and Japanese trade associations for the cosmetic industry sponsor this meeting in order to gain mutual understanding and work toward harmonizing global regulations of cosmetics. There were no spectacular announcements, unlike the last conference in 2000 in Malta when Japan announced significant changes in their cosmetic regulations.
Dec 23, 2005 | 05:10 PM CST
European Adaptation to Technical Progress
By: David C. Steinberg, Steinberg & Associates
Starting with January 2003, The European Union discontinued the numbering of their Adaptation to Technical Progress (ATP). This was done as the 7th Amendment superceded some of the approved ATP’s and made the numbering system out of sync. Since I last reported on the 7th Amendment changes, the EU Commission has issued two critical changes. ATP’s are the way to change the Annexes in the Cosmetic Directive.
Dec 23, 2005 | 04:23 PM CST
US and EU Regulations Update
By: David C. Steinberg, Steinberg & Associates
United States – OTC Drug Review Call for Data On December 31, 2003, the FDA announced a call for data for an OTC drug review, for drugs that have not been reviewed as of this date. These include drugs sold before 5/11/72 (when the OTC drug review began) and identified by OTC category. Also included are OTC drugs marketed before 12/4/75 and described the DA’s general regulatory policy. The call for data covers these categories of ingredients, some of which have been considered to be cosmetics, not drugs: nasal moisturizer drug products, urinary analgesic/antiseptic drug products, urinary acidifiers and alkalinizers, aloe vera and urea, wrinkle remover products, lubricants and vaginal moisturizers.
Dec 23, 2005 | 03:01 PM CST
Updates from Europe and the United States
By: David C. Steinberg, Steinberg & Associates
European Updates The European Union (EU) Commission has not issued any changes to the Annexes of the Cosmetic Directive since September 2003 and lags in publishing many changes that have been approved. Adaptation to Technical Progress (opinions put through the EU and Ad Hoc committee review process) will be further delayed because they must be published in all EU languages. As of May 2004, the EU expanded from 15 to 25 countries, complicating the translation list.
Dec 13, 2005 | 11:14 PM CST
Cosmeceutical Regulations–A Global Overview
By: David C. Steinberg, Steinberg & Associates
Cosmeceuticals are not regulated as such in the Europeon Union, United States or Japan. In the EU, most are considered cosmetics; in the United States, most are seen as drugs that probably have not been approved by the U.S. Food and Drug Administration (FDA). In Japan, they are regulated as quasi-drugs. As you can see, we go from the extremes of limited regulated cosmetics in the EU to pre-approvals in Japan, and fi nally a lack of enforcement in the United States.
